



26 April 2024

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Block Listing Six Monthly Return

Avacta Group plc (AIM: AVCT), a life sciences developing innovative, targeted oncology drugs and powerful diagnostics, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of <i>applicant</i> :		Avacta Group plc		
Name of scheme:		EMI scheme		
Period of return:	From:	28 October 2023		27 April 2024
Balance of unallotted securities under scheme(s) from previous return:		797,922		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		113,808		
<u>Less:</u> Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		108,724		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:		911,730		

Name of <i>applicant</i> :		Avacta Group plc		
Name of scheme:		LTIP scheme		
Period of return:	From:	28 October 2023		27 April 2024
Balance of unallotted securities under scheme(s):		5,277,257		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		6,500,000		
<u>Less:</u> Number of <i>securities</i> issued/allotted		2,058,000		

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	2,036,000
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	11,777,257

Name of contact:	Tony Gardiner, Company Secretary
Telephone number of contact:	+ 44 (0) 1904 217070

Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc

Tel: +44 (0) 1904 21 7070

Alastair Smith, Chief Executive Officer

www.avacta.com

Tony Gardiner, Chief Financial Officer

Michael Vinegrad, Group Communications Director

Stifel Nicolaus Europe Limited (Nomad and Joint Corporate Broker)

Tel: +44 (0) 207 710 7600

Nicholas Moore / Nick Adams / Samira Essebiyea /
Nick Harland / Ben Good

www.stifel.com

Peel Hunt (Joint Corporate Broker)

Tel: +44 (0) 207 418 8900

James Steel / Chris Golden / Patrick Birkholm

www.peelhunt.com

ICR Consilium (Media and IR)

avacta@consilium-comms.com

Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

About Avacta Group plc - <https://www.avacta.com>

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

Avacta has two divisions focused on therapeutics and diagnostics.

Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

Avacta Diagnostics: focused on supporting healthcare professionals and broadening access to diagnostics.

Avacta has two proprietary platforms, pre|CISION™ and Affimer®.

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

To register for news alerts by email go to <https://avacta.com/investors/investor-news-email-alerts/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRPPUAGCUPCPUA